Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Newton
Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients With Relapsed B-Cell Lymphoma Treated With Rituximab
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Results of Phase Ii Study of Combined Immunotherapy With Rituximab Plus Lymphokine-Activated Killer Cells as Maintenance in Follicular Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma
American Journal of Hematology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Adoptive Immunotherapy With Cytokine-Induced Killer Cells for Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Imaging Pattern of Radiolabelled Lymphokine-Activated Killer Cells in Patients With Metastatic Malignant Melanoma
European Journal of Nuclear Medicine and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
Therapeutic Effect of Lymphokine-Activated Killer Cells Treated With Low-Dose Ionizing Radiation on Osteosarcoma
Oncology Letters
Cancer Research
Oncology
Substance P Increases in Vitro Lymphokine-Activated-Killer (LAK) Cell Cytotoxicity Against Fresh Colorectal Cancer Cells
Journal of Surgical Research
Surgery
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
